Business
Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit
First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota,
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"First esophageal precancer detection event utilizing an EsoGuard mobile test unit to be hosted today by Florida Digestive Health Specialists in Sarasota, Florida\nNEW YORK, June 5, 2023 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid Diagnostics\" or \"Lucid\"), a commercial-stage cancer prevention diagnostics company and a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced the launch of its first EsoGuard® #CheckYourFoodTube Mobile Test Unit serving patients and practices in the Greater Central Florida area. Florida Digestive Health Specialists (\"FDHS\"), Florida's largest gastroenterology network, will co-host the inaugural precancer detection event at the Gastroenterology Associates of Sarasota offices in Sarasota, Florida under the direction of Dr. Scott Corbett, Chief of Gastroenterology at Sarasota Memorial Hospital.\n\n \n \n \n \n \n \n\n \n\"This expansion into mobile testing is yet another example of our relentless commitment to bringing EsoGuard testing to at-risk patients in order to detect precancer and prevent devastating esophageal cancer,\" said Lishan Aklog, M.D., Lucid's Chairman & Chief Executive Officer. \"We believe that mobile testing will strongly complement our satellite Lucid Test Center and high-volume precancer detection event programs. With these programs, we seek to expand patient access and drive EsoGuard test volume growth by lowering barriers and bringing testing directly to patients who are recommended for esophageal precancer testing by established clinical practice guidelines. We greatly appreciate the efforts of healthcare providers like Dr. Corbett and his colleagues at FDHS for supporting this important initiative.\"\nEsoGuard is the first and only commercially available diagnostic test capable of serving as a widespread tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk individuals. During the testing event, at-risk patients will undergo a brief, noninvasive cell collection procedure performed by Lucid personnel in the mobile unit using the EsoCheck® Esophageal Cell Collection Device. Samples will then be sent to Lucid's dedicated CLIA-certified, CAP-accredited molecular diagnostic laboratory in Lake Forest, California, where the EsoGuard Esophageal DNA Test will be performed. Shortly thereafter, p...